Joint Biosciences’ OVV-01 Receives FDA Fast Track Designation for Soft Tissue Sarcoma Trial
Shanghai-based Joint Biosciences Ltd., a developer of tumor combined immunotherapies, has announced receiving fast track...
Sino Biopharmaceutical’s Culmerciclib Shows Positive Results in Phase III Breast Cancer Trial
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has revealed positive results from the Phase III TQB3616-III-02...
Humanwell Healthcare Receives NMPA Approval for Caplyta Generic in Schizophrenia Trial
China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) has announced receiving clinical trial approval from...
Clover Biopharmaceuticals Receives Termination Notice from GAVI for COVID-19 Vaccine Agreement
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) announced receiving a one-month prior written notice dated March...
Simcere Pharmaceutical Group Reports Steady Revenue Amid R&D Investment Shift
China-based Simcere Pharmaceutical Group (HKG: 2096) has released its 2024 financial performance report, recording RMB...
Henlius Biotech Reports 6.1% Revenue Growth with Strong Oncology Product Sales
Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of...
Sichuan Kelun-Biotech Reports 25.5% Revenue Growth with Key Drug Approvals
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has released its 2024 financial report, recording...
China’s NHSA Releases 2024 Healthcare Security Bulletin Highlighting Insurance Coverage and Reimbursement
China’s National Healthcare Security Administration (NHSA) has released its 2024 “Healthcare Security Development Statistical Bulletin.”...
Jenscare Scientific’s Ken Valve Receives NMPA Marketing Approval
Jenscare Scientific Co., Ltd (HKG: 9877), a Ningbo-based structural heart disease device maker, has announced...
SineuGene Therapeutics’ SNUG01 Receives FDA Clearance for ALS Clinical Study
Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced last week that...
GSK’s Nucala Accepted for EMA Review for COPD Treatment
UK-based GSK plc’s (LON: GSK, NYSE: GSK) application for expanding the use of its anti-interleukin-15...
Opella and JD Healthcare Collaborate to Enhance Fatty Liver Awareness in China
Opella, the consumer health business of French giant Sanofi (EPA: SAN, NASDAQ: SNY), held a...
Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil...
Shanghai Ark Biopharmaceutical’s AK0901 Meets Phase III Endpoints in ADHD Trial
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has announced the completion of a Phase III study...
WuXi XDC Reports 90.8% Revenue Surge, Expanding in ADC Market
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA...
Suzhou Xueji Biotech’s XJ-MK-002 Gets FDA Orphan Drug Designation for CAMT
China-based cell therapy developer Suzhou Xueji Biotechnology Co., Ltd’s (HemaCell) XJ-MK-002, described as the world’s...
Beijing Sungen Biomedical’s SGC001 Receives FDA Fast Track Designation for AMI Treatment
China-based Beijing Sungen Biomedical Technology Co., Ltd, an antibody developer incubated by Hotgen Biotech Co.,...
CanSino Biologics Partners with Grand Life Sciences to Commercialize Tetanus Vaccine in Greater China
Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an...
AllianThera Biopharma Starts Global Phase I Trial for ATB102 in Inflammatory Bowel Diseases
Suzhou-based startup AllianThera Biopharma has announced the first patient dosing in a global Phase I...
Jiangsu Hengrui Pharmaceuticals’ Ivarmacitinib Receives NMPA Approval for Ankylosing Spondylitis
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving marketing approval from the National...